Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences announced that Cigna now covers excimer laser therapy for treating localized vitiligo, previously deemed cosmetic. The policy allows for up to 12 weeks of treatment, with extensions possible based on clinical response. This change could significantly expand the market for STRATA, as approximately $38,000 can be reimbursed per patient over a year. The company highlights its unique position, being the sole licensee of vitiligo-related patents, and aims to reach more dermatology clinics and patients across the U.S.
STRATA Skin Sciences announced a new direct distribution contract with JMEC Co., Ltd. for its XTRAC® and VTRAC® products in Japan. This contract aims to enhance brand value, leveraging STRATA's strong balance sheet and JMEC's distribution network. With over 12,000 dermatologists in Japan, STRATA expects recurring revenue impacts by the end of 2020. The treatment procedure covered by national health insurance is priced at $33. The partnership builds on a 15-year relationship to expand treatment access for vitiligo and psoriasis patients in a growing market.
STRATA Skin Sciences (NASDAQ: SSKN) will release its second quarter financial results for the period ended June 30, 2020, on August 11 before market open. The company focuses on innovative products for dermatological conditions, with a primary offering being the XTRAC excimer laser system. This technology addresses conditions like psoriasis and vitiligo, impacting over 35 million patients in the U.S. STRATA has established a network of over 822 clinics and more than 2,000 devices worldwide, utilizing a direct-to-consumer advertising model to drive awareness and increase physician introductions.
STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2020 results with total revenue of $6.7 million, a 10.1% decline from Q1 2019. However, global recurring revenue grew by 7.3% to $5.7 million. Gross margins improved to 65.4%, with recurring gross margins at 68.4%. The company's net loss narrowed to $1.0 million, down 22.4% from the previous year. As of March 31, 2020, STRATA had $15.6 million in cash and received a $2 million PPP loan to support operations during the pandemic. The firm is optimistic about business recovery as restrictions lift.